InsidersTradesSigma
Total declarations
Company
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by FINE N SCOTT, Chairman & CEO. Insider active across 1 companies, notably Cyclo Therapeutics, Inc.. Cumulatively, 12 reports have been recorded. Total volume traded: €277k. The latest transaction was disclosed on 7 February 2022 — Acquisition. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
€32,29610,334 shares@ €3.125223.3% of flow
Common Stock
SEC:0001437749-22-002613·
Ideal exit: 4 Nov 2022 (T+270)
€32,29610,334 shares@ €3.125211.7% of flow
Common Stock
SEC:0001437749-22-002613:0·
Ideal exit: 4 Nov 2022 (T+270)
€17,1675,000 shares@ €3.433512.4% of flow
Common Stock
SEC:0001437749-22-001188·
Ideal exit: 16 Oct 2022 (T+270)
€17,1675,000 shares@ €3.43356.2% of flow
Common Stock
SEC:0001437749-22-001188:0·
Ideal exit: 16 Oct 2022 (T+270)
€17,2725,000 shares@ €3.454312.5% of flow
Common Stock
SEC:0001437749-21-028622·
Ideal exit: 11 Sept 2022 (T+270)
€17,2725,000 shares@ €3.45436.2% of flow
Common Stock
SEC:0001437749-21-028622:0·
Ideal exit: 11 Sept 2022 (T+270)
€21,7775,000 shares@ €4.355315.7% of flow
Common Stock
SEC:0001437749-21-027709·
Ideal exit: 29 Aug 2022 (T+270)
€21,7775,000 shares@ €4.35537.9% of flow
Common Stock
SEC:0001437749-21-027709:0·
Ideal exit: 29 Aug 2022 (T+270)
€23,0905,000 shares@ €4.618116.7% of flow
Common Stock
SEC:0001437749-21-027140·
Ideal exit: 16 Aug 2022 (T+270)
€23,0905,000 shares@ €4.61818.3% of flow
Common Stock
SEC:0001437749-21-027140:0·
Ideal exit: 16 Aug 2022 (T+270)
€26,8615,000 shares@ €5.372319.4% of flow
Common Stock
SEC:0001437749-21-022183·
Ideal exit: 12 Jun 2022 (T+270)
€26,8615,000 shares@ €5.37239.7% of flow
Common Stock
SEC:0001437749-21-022183:0·
Ideal exit: 12 Jun 2022 (T+270)
12 of 12 declarations
About FINE N SCOTT
Scott N. Fine serves as the Chief Executive Officer of Cyclo Therapeutics, Inc. In this role, he leads the strategic operations of the company, which specializes in developing treatments for rare diseases. Scott is responsible for the overall vision of the company and the implementation of its business objectives. His leadership is essential in positioning Cyclo Therapeutics as a key player in the biotechnology sector.
